Randomized controlled trial of homocysteine-lowering vitamin treatment in elderly patients with vascular disease

American Journal of Clinical Nutrition

Volumn 82, Issue 6, 2005, Pages 1320-1326

  Stott, David J ^a,b   MacIntosh, Graham ^a   Lowe, Gordon D O ^a   Rumley, Ann ^a   McMahon, Alex D ^a   Langhorne, Peter ^a   Tait, R Campbell ^b   O'Reilly, Denis St J ^b   Spilg, Edward G ^c   MacDonald, Jonathan B ^c   MacFarlane, Peter W ^a   Westendorp, Rudi G J ^d  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b GLASGOW ROYAL INFIRMARY   (United Kingdom)

^c GARTNAVEL GENERAL HOSPITAL   (United Kingdom)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cognitive function; Elderly; Folic acid; Homocysteine; Randomized controlled trial; Riboflavin; Vitamin B 12; Vitamin B 6

Indexed keywords

CYANOCOBALAMIN; FIBRINOGEN; FOLIC ACID; HOMOCYSTEINE; PYRIDOXINE; RIBOFLAVIN; VON WILLEBRAND FACTOR; VITAMIN B COMPLEX;

AGED; ARTICLE; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; INTERVIEW; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; VASCULAR DISEASE; ANALYSIS OF VARIANCE; BLOOD; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG POTENTIATION; TREATMENT OUTCOME;

AGED; ANALYSIS OF VARIANCE; COGNITION; DOUBLE-BLIND METHOD; DRUG SYNERGISM; FEMALE; FIBRINOGEN; FOLIC ACID; HOMOCYSTEINE; HUMANS; MALE; RIBOFLAVIN; TREATMENT OUTCOME; VASCULAR DISEASES; VITAMIN B 12; VITAMIN B 6; VITAMIN B COMPLEX; VON WILLEBRAND FACTOR;

EID: 33644693101     PISSN: 00029165     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajcn/82.6.1320     Document Type: Article

References (36)

1. Boushey CJ, Beresford SAA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: Probable benefits of increasing folic acid intakes. JAMA 1995;274:1049-57.
2. Clarke R, Harrison G, Richards S, Vital Trial Collaborative Group. Effect of vitamins and aspirin onmarkers of platelet activation, oxidative stress and homocysteine in people at high risk of dementia. J Intern Med 2003;254:67-75.
3. Hassan A, Hunt BJ, O'Sullivan M, et al. Homocysteine is a risk factor for cerebral small vessel disease, acting via endothelial dysfunction. Brain 2004;127:1-9.
4. Rogers GM, Conn MT. Homocysteine, an atherogenic stimulus, reduces protein C activation by arterial and venous endothelial cells. Blood 1995;75:895-901.
5. Naurath HJ, Joosten E, Riezler R, Stabler SP, Allen RH, Lindenbaum J. Effects of vitamin B12, folate, and vitamin B6 supplements in elderly people with normal serum vitamin concentrations. Lancet 1995;346:85-9.
6. Nilsson K, Gustafson L, Faldt R, Andersson A, Hultberg B. Plasma homocysteine in relation to serum cobalamin and blood folate in a psychogeriatric population. Eur J Clin Invest 1994;24:600-6.
7. Moat SJ, Ashfield-Watt PA, Powers HJ, Newcombe RG, McDowell IF. Effect of riboflavin status on the homocysteine-lowering effect of folate in relation to the MTHFR (C677T) genotype. Clin Chem 2003;49:295-302.
8. Gartler SM, Hornany SK, Motulsky AG. Effect of chronologic age on induction of cystathionine synthase, uroporphyrinogen 1 synthase, and glucose-G-phosphate dehydrogenase activities in lymphocytes. Proc Natl Acad Sci U S A 1981;78:1416-9.
9. Moher D, Schulz KF, Altman DG, for the CONSORT Group. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet 2001;357:1191-4.
10. Fillenbaum GG, Smyer MA. The development, validity and reliability of the OARS multidimentional functional assessment questionnaire. J Gerontol 1981;36:428-34.
11. Madigan SM, Tracey F, McNulty H, Eaton-Evans J, Coulter J, McCartney HSJ. Riboflavin and vitamin B-6 intakes and status and biochemical response to riboflavin supplementation in free-living elderly people. Am J Clin Nutr 1998;68:389-95.
12. Gallo JJ, Breitner JCS. Alzheimer' s disease in the NAS-NRC Registry of ageing twin veterans, IV. Performance characteristics of a two-stage telephone screening procedure for Alzheimer's dementia. Psychol Med 1995;25:1211-9.
13. Smith A. The Symbol Digit Modalities Test. A neuropsychological test for economic screening of learning and other cerebral disorders. Learning Disord 1968;3:82-91.
14. Houx PJ, Shepherd J, Blauw GJ, et al. Testing cognitive function in elderly populations: The PROSPER study. J Neurol Neurosurg Psychiatry 2002;73:385-9.
15. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22.
16. Brandt J, Spencer M, Folstein M. The Telephone Interview for Cognitive Status. Neuropsychiatry Neuropsychol Behav Neurol 1988;1:111-7.
17. McKinley MC, McNulty H, McPartlin J, Strain JJ, Scott JM. Effect of riboflavin supplementation on plasma homocysteine in elderly people with low riboflavin status. Eur J Clin Nutr 2002;56:850-6.
18. McNulty H, McKinley MC, Wilson B, et al. Impaired functioning of thermolabile methylenetetrahydrofolate reductase is dependent on riboflavin status: implications for riboflavin requirements. Am J Clin Nutr 2002;76:436-41.
19. Baker F, Picton D, Blackwood S, et al. Blinded comparison of folic acid and placebo in patients with ischaemic heart disease: an outcome trial. Circulation 2002;106:II-741.
20. Anderson JL, Jensen KR, Carlquist JF, Bair TL, Horne BD, Muhlestein JB. Effect of folic acid fortification of food on homocysteine-related mortality. Am J Med 2004;116:158-64.
21. Jacques PF, Selhub J, Bostom A, Wilson PWF, Rosenberg IH. The effect of folic acid fortification on plasma folate and total homocysteine concentrations. N Engl J Med 1999;340:1449-54.
22. Doshi S, McDowell I, Moat S, Lewis M, Goodfellow J. Folate improves endothelial function in patients with coronary heart disease. Clin Chem Lab Med 2003;41:1505-12.
23. van Dijk RA, Rauwerda JA, Steyn M, Twisk JW, Stehouwer CD. Long-term homocysteine-lowering treatment with folic acid plus pyridoxine is associated with decreased blood pressure but not with improved brachial artery endothelium-dependent vasodilation or carotid artery stiffness: a 2-year, randomized, placebo-controlled trial. Arterioscler Thromb Vasc Biol 2001;21:2072-9.
24. Klerk M, Verhoef P, Verbruggen B, et al. Effect of homocysteine reduction by B-vitamin supplementation on markers of clotting activation. Thromb Haemost 2002;88:230-5.
25. Clark R, Smith DA, Jobst KA, Refsum H, Sutton L, Ueland PM. Folate, vitamin B12, and serum total homocysteine levels in confirmed Alzheimer's disease. Arch Neurol 1998;55:1449-55.
26. McCaddon A, Davies G, Hudson P, Tandy S, Cattell H. Total serum homocysteine in senile dementia of Alzheimer type. Int J Geriatr Psychiatry 1998;13:235-9.
27. Almeida OP, Lautenschlager N, Flicker L, et al. Association between homocysteine, depression, and cognitive function in community-dwelling older women from Australia. J Am Geriatr Soc 2004;52:327-8.
28. Kalmijn S, Launer LJ, Lindemans J, Bots ML, Hofman A, Breteler MM. Total homocysteine and cognitive decline in a community-based sample of elderly subjects: the Rotterdam Study. Am J Epidemiol 1999;150:283-9.
29. Malouf M, Grimley EJ, Areosa SA. Folic acid with or without vitamin B12 for cognition and dementia. Cochrane Database Syst Rev 2003;4: CD004514.
30. Malouf R, Grimley Evans J. The effect of vitamin B6 on cognition. Cochrane Database Syst Rev 2003;4:CD004393.
31. Bryan J, Calvaresi E, Hughes D. Short-term folate, vitamin B-12 or vitamin B-6 supplementation slightly affects memory performance but not mood in women of various ages. J Nutr 2002;132:1345-56.
32. Sommer BR, Hoff AL, Costa M. Folic acid supplementation in dementia: a preliminary report. J Geriatr Psychiatry Neurol 2003;16:156-9.
33. Fioravanti M, Ferrario E, Massaia M, et al. Low folate levels in the cognitive decline of elderly patients and efficacy of folate as a treatment for improving memory deficits. Arch Gerontol Geriatr 1997;26:1-13.
34. Toole JFM, Malinow MR, Chambless LE, et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA 2004;291:565-75.
35. Liem A, Reynierse-Buitenwerf GH, Zwinderman AH, Jukema JW, van Veldhuisen DJ. Secondary prevention with folic acid: effects on clinical outcomes. J Am Coll Cardiol 2003;41:2105-13.
36. Hankey G, Eikelboom JW. Homocysteine and vascular disease. Lancet 1999;354:407-13.